Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/Pioglitazone - Boryung Pharmaceutical

Drug Profile

Dapagliflozin/Pioglitazone - Boryung Pharmaceutical

Alternative Names: BR-3003

Latest Information Update: 25 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boryung Pharmaceutical
  • Class Antihyperglycaemics; Benzhydryl compounds; Chlorobenzenes; Glucosides; Heart failure therapies; Obesity therapies; Pyrans; Small molecules; Thiazolidinediones; Urologics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 20 Oct 2023 Dapagliflozin/Pioglitazone is still in phase III trials for Type 2 Diabetes mellitus in South Korea (Boryung Pharmaceutical pipeline, October 2023)
  • 03 Jul 2022 Boryung Pharmaceutical completes a phase I trial for Type 2 diabetes mellitus in the South Korea (NCT05411965)
  • 11 Feb 2021 BR 3003 is available for licensing as of 11 Feb 2021. http://www.boryung.co.kr/eng/rnd/pipeline.do
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top